Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 112 articles:
HTML format



Single Articles


    March 2024
  1. HOLM I, Hernroth B, Rosander A, Tassidis H, et al
    Manganese as a Possible Anticancer Enhancer in Docetaxel Treatment of Prostate Cancer Cells.
    Anticancer Res. 2024;44:953-962.
    PubMed     Abstract available


  2. YAMAMICHI G, Kato T, Watabe T, Hatano K, et al
    Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer.
    Anticancer Res. 2024;44:879-888.
    PubMed     Abstract available


    February 2024
  3. DELL'ATTI L
    Biparametric MRI for Local Staging of Prostate Cancer: Current Status and Future Applications.
    Anticancer Res. 2024;44:463-470.
    PubMed     Abstract available


  4. KUROKAWA G, Mori K, Sasaki H, Nakano J, et al
    Effectiveness of Magnetic Resonance Imaging/Ultrasound-guided Target Biopsy in Detecting Clinically Significant Prostate Cancer.
    Anticancer Res. 2024;44:679-686.
    PubMed     Abstract available


  5. SAKAMOTO S, Ando K, Pae S, Zhao X, et al
    Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer.
    Anticancer Res. 2024;44:639-647.
    PubMed     Abstract available


    January 2024
  6. OKA D, Sekine Y, Tsuji Y, Nakayama H, et al
    Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer Cells via Inhibition of RAD51 Expression.
    Anticancer Res. 2024;44:93-98.
    PubMed     Abstract available


  7. REINIKAINEN P, Lehtinen I, Luukkaala T, Kellokumpu-Lehtinen PL, et al
    Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer.
    Anticancer Res. 2024;44:139-150.
    PubMed     Abstract available


    December 2023
  8. MIYAZAWA Y, Sekine Y, Oka D, Nakazawa S, et al
    Simvastatin Induces Autophagy and Inhibits Proliferation in Prostate Cancer Cells.
    Anticancer Res. 2023;43:5377-5386.
    PubMed     Abstract available


  9. MAEDA-MINAMI A, Nishikawa T, Ishikawa H, Mutoh M, et al
    Angiotensin II Receptor Blockers Cause Changes in Prostate-specific Antigen Levels: A Retrospective Cohort Study.
    Anticancer Res. 2023;43:5629-5636.
    PubMed     Abstract available


  10. FUKUI Y, Yamada Y, Sakamoto S, Horikoshi T, et al
    Preoperative PI-RADS v2.1 Scoring System Improves Risk Classification in Patients Undergoing Radical Prostatectomy.
    Anticancer Res. 2023;43:5705-5712.
    PubMed     Abstract available


  11. SMULDERS-SRINIVASAN TK, Jenkinson SE, Brown LJ, Lenis VP, et al
    PDIA6 and Maspin in Prostate Cancer.
    Anticancer Res. 2023;43:5331-5340.
    PubMed     Abstract available


    November 2023
  12. YAMAMOTO T, Umezawa R, Shimada S, Takahashi N, et al
    The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer.
    Anticancer Res. 2023;43:5115-5125.
    PubMed     Abstract available


    October 2023
  13. KANO H, Izumi K, Nakagawa R, Toriumi R, et al
    Role of Positive Biopsy Core Ratio in Prostate Cancer Patients.
    Anticancer Res. 2023;43:4619-4626.
    PubMed     Abstract available


  14. NAGATA Y, Jojima K, Matsukawa T, Tomisaki I, et al
    Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2023;43:4573-4581.
    PubMed     Abstract available


  15. KUSUHARA Y, Fukawa T, Fukumori T, Ueno Y, et al
    Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in Intermediate-risk Prostate Cancer.
    Anticancer Res. 2023;43:4627-4635.
    PubMed     Abstract available


  16. URABE F, Kobayashi D, Iwatani K, Imai YU, et al
    The Efficacy and Safety of a Low Relative Dose Intensity of Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2023;43:4611-4617.
    PubMed     Abstract available


    September 2023
  17. SISSUNG TM, Lochrin S, Liu T, Schmidt K, et al
    GNRH2 Polymorphism in Men With Prostate Cancer Treated With Androgen Deprivation Therapy.
    Anticancer Res. 2023;43:4023-4030.
    PubMed     Abstract available


  18. KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
    Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
    Anticancer Res. 2023;43:4249-4254.
    PubMed     Abstract available


  19. FERINI G, Zagardo V, Valenti V, Aiello D, et al
    Towards Personalization of Planning Target Volume Margins Fitted to the Abdominal Adiposity in Localized Prostate Cancer Patients Receiving Definitive or Adjuvant/Salvage Radiotherapy: Suggestive Data from an ExacTrac vs. CBCT Comparison.
    Anticancer Res. 2023;43:4077-4088.
    PubMed     Abstract available


  20. FUJIMOTO N, Tsubonuma Y, Nagata Y, Minato A, et al
    Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.
    Anticancer Res. 2023;43:3841-3847.
    PubMed     Abstract available


    August 2023
  21. OGATA T, Aizawa R, Nakamura K, Kobayashi T, et al
    Impact of Long-term Adjuvant Hormonal Therapy in High-dose IMRT for Unfavorable Locally Advanced Prostate Cancer.
    Anticancer Res. 2023;43:3589-3596.
    PubMed     Abstract available


  22. HAAPASALMI S, Lehto JT, Metsanoja R, Kellokumpu-Lehtinen PI, et al
    End-of-life Decision-making Differs Between a Cancer and a Dementia Patient: Influences of the Physician's Background Factors.
    Anticancer Res. 2023;43:3631-3638.
    PubMed     Abstract available


    July 2023
  23. SUZUKI H, Urabe F, Iwatani K, Miyajima K, et al
    Treatment Results of High-dose-rate Brachytherapy and External Beam Radiation With Long-term Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer.
    Anticancer Res. 2023;43:3135-3143.
    PubMed     Abstract available


  24. ROCCA C, Rocca G, Zampieri P, Dell'atti L, et al
    Somatic and Germline Variants Affect Prognosis and Susceptibility in Prostate Cancer.
    Anticancer Res. 2023;43:2941-2949.
    PubMed     Abstract available


  25. ENEI Y, Urabe F, Miki K, Suzuki H, et al
    Effect of Adequate Local Radiation Dose on Oncological Outcomes in Localized Prostate Cancer Patients Treated With Low-dose-rate Brachytherapy.
    Anticancer Res. 2023;43:3159-3166.
    PubMed     Abstract available


    June 2023
  26. NATSAGDORJ A, Izumi K, Hiratsuka K, Naito R, et al
    The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
    Anticancer Res. 2023;43:2561-2569.
    PubMed     Abstract available


  27. NOHL EK, Behring J, Kameri E, Koditz B, et al
    Improved Analysis of Prostate Cancer: VIM3, ATG7 and P53 Form a Complex and Activate miRNA 371a-3p.
    Anticancer Res. 2023;43:2407-2416.
    PubMed     Abstract available


  28. SHIMADA T, Naito R, Toriumi R, Nakagawa R, et al
    Novel alpha-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells.
    Anticancer Res. 2023;43:2433-2444.
    PubMed     Abstract available


  29. TAKAKUSAGI Y, Koge H, Kano K, Shima S, et al
    Safety of Carbon-ion Radiotherapy for Prostate Cancer After Rectal Cancer Surgery.
    Anticancer Res. 2023;43:2691-2695.
    PubMed     Abstract available


    May 2023
  30. AL-SALOOL A, Soror T, Yu NY, Rades D, et al
    Prevalence and Risk Factors of Emotional Distress in Patients With Prostate Cancer Assigned to External-beam Radiotherapy With or Without High-dose Rate Brachytherapy.
    Anticancer Res. 2023;43:2103-2109.
    PubMed     Abstract available


  31. AHREND H, Appel B, Jung L, Muller S, et al
    Reinforcement of the Tumor Suppressing Properties of microRNA-1 by Substitution at the C2' Position of Varying Ribose Residues in Chemically Synthesized microRNA-1 Molecules.
    Anticancer Res. 2023;43:1909-1918.
    PubMed     Abstract available


  32. MATSUMOTO S, Matsufuji N, Koba Y, Tsuji H, et al
    In Vivo Dosimetry in the Urethra During Prostate Carbon Ion Radiotherapy.
    Anticancer Res. 2023;43:2259-2264.
    PubMed     Abstract available


    April 2023
  33. MIYAJIMA K, Yanagisawa T, Suzuki H, Fukuokaya W, et al
    Comparison of Quality of Life and Injection Site Reactions After Switching from Degarelix 80 mg to 480 mg in Advanced Prostate Cancer: A Prospective Trial.
    Anticancer Res. 2023;43:1611-1621.
    PubMed     Abstract available


  34. REZAC J, Hanouskova L, Vesely S, Kotaska K, et al
    Serum Thymidine Kinase 1 - Potential Prostate Cancer Biomarker: A Clinical Study.
    Anticancer Res. 2023;43:1675-1680.
    PubMed     Abstract available


  35. YANG HC, Chang LW, Li JR, Wang SS, et al
    Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
    Anticancer Res. 2023;43:1809-1816.
    PubMed     Abstract available


  36. AKINO Y, Shiomi H, Mabuchi N, Masai N, et al
    Optimization of Fluence Map for CyberKnife Raster Scanning Intensity Modulated Radiotherapy.
    Anticancer Res. 2023;43:1637-1642.
    PubMed     Abstract available


    March 2023
  37. YAMASHITA SN, Tanaka Y, Kitagawa T, Baron B, et al
    Down-regulating Effect of a Standardized Extract of Cultured Lentinula edodes mycelia on Cortactin in Prostate Cancer Cells Is Dependent on Malignant Potential.
    Anticancer Res. 2023;43:1159-1166.
    PubMed     Abstract available


  38. NAKAGAWA R, Iwamoto H, Naito R, Kadomoto S, et al
    Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?
    Anticancer Res. 2023;43:1351-1359.
    PubMed     Abstract available


    January 2023
  39. TACHIBANA A, Hori S, Nakai Y, Miyake M, et al
    Effects on Life Expectancy of Treatment Decisions in Patients With Non-metastatic Prostate Cancer.
    Anticancer Res. 2023;43:473-483.
    PubMed     Abstract available


  40. DE CICCO L, Marzoli L, Lorusso R, Mancuso RM, et al
    CBCT-based Prostate IGRT With and Without Implanted Markers: Assessment of Geometric Corrections and Time for Completion.
    Anticancer Res. 2023;43:405-408.
    PubMed     Abstract available


  41. FURINI HH, Fukushima KSSQ, DE Nobrega M, DE Souza MF, et al
    An MGMT Allelic Variant Can Affect Biochemical Relapse in Prostate Cancer Patients.
    Anticancer Res. 2023;43:369-379.
    PubMed     Abstract available


  42. NASCIMENTO-GONCALVES E, Seixas F, DA Costa RMG, Pires MJ, et al
    Appraising Animal Models of Prostate Cancer for Translational Research: Future Directions.
    Anticancer Res. 2023;43:275-281.
    PubMed     Abstract available


  43. NAGATA Y, Matsukawa T, Tomisaki I, Fujimoto N, et al
    Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2023;43:429-436.
    PubMed     Abstract available


  44. PALUMBO I, Ruggiero C, Festa E, DE Fano M, et al
    Bone Health Care Pathway for Non-metastatic Prostate Cancer Patients on Radiation and Androgen Deprivation Therapy.
    Anticancer Res. 2023;43:493-499.
    PubMed     Abstract available


  45. XIAO H, Wu Z, Wang Q, Zhou C, et al
    Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage.
    Anticancer Res. 2023;43:389-403.
    PubMed     Abstract available


  46. DELL'ATTI L, Aguiari G
    The Role of Genetic Polymorphisms in the Diagnosis and Management of Prostate Cancer: An Update.
    Anticancer Res. 2023;43:317-322.
    PubMed     Abstract available


  47. LIAO CH, Chang WS, Hsu WL, Hu PS, et al
    Association of Matrix Metalloproteinase-7 Genotypes With Prostate Cancer Risk.
    Anticancer Res. 2023;43:381-387.
    PubMed     Abstract available


  48. FERDA J, Hes O, Hora M, Ferdova E, et al
    Assessment of Prostate Carcinoma Aggressiveness: Relation to (68)Ga-PSMA-11-PET/MRI and Gleason Score.
    Anticancer Res. 2023;43:449-453.
    PubMed     Abstract available


  49. CHANG LW, Wang SS, Yang CK, Lu K, et al
    Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
    Anticancer Res. 2023;43:485-491.
    PubMed     Abstract available


  50. YAMAMICHI G, Kato T, Uemura M, Nonomura N, et al
    Diagnosing and Prognosing Bone Metastasis in Prostate Cancer: Clinical Utility of Blood Biomarkers.
    Anticancer Res. 2023;43:283-290.
    PubMed     Abstract available


  51. YE L, Sanders AJ, Jiang WG
    Transglutaminase-4 (Prostate Transglutaminase), a Potential Biological Factor and Clinical Indicator for the Diagnosis and Prognosis of Prostate Cancer.
    Anticancer Res. 2023;43:291-296.
    PubMed     Abstract available


  52. LI K, Luan Q, Zheng J, Li R, et al
    Clinical Value of Magnetic Resonance Imaging Combined With Serum Prostate-specific Antigen, Epithelial Cadherin and Early Prostate Cancer Antigen 2 In Diagnosis of Prostate Cancer.
    Anticancer Res. 2023;43:441-447.
    PubMed     Abstract available


  53. NEUBERGER M, Frey L, Nitschke K, Wessels F, et al
    Integrin Expression in Localized Prostate Cancer: A TCGA and MSKCC Cohort-based Exploratory In Silico Analysis.
    Anticancer Res. 2023;43:417-428.
    PubMed     Abstract available


  54. VALERIO MR, Serretta V, Arico D, Fazio I, et al
    A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate Cancer.
    Anticancer Res. 2023;43:501-508.
    PubMed     Abstract available


  55. DE LA PINTA C
    Radiotherapy in Prostate Brain Metastases: A Review of the Literature.
    Anticancer Res. 2023;43:311-315.
    PubMed     Abstract available


  56. SUCKOW MA, Hiles MC
    Use of Conditioned Extracellular Matrix as a Tissue-engineered Tumor Matrisome for Prostate Cancer and Melanoma Immunotherapy.
    Anticancer Res. 2023;43:335-341.
    PubMed     Abstract available


  57. LI PH, Liao CH, Huang WC, Chang WS, et al
    Association of Matrix Metalloproteinase-2 Genotypes With Prostate Cancer Risk.
    Anticancer Res. 2023;43:343-349.
    PubMed     Abstract available


  58. LEECH M, Leijenaar RTH, Hompland T, Gaffney J, et al
    Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring.
    Anticancer Res. 2023;43:351-357.
    PubMed     Abstract available


  59. MASUDA H
    Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy.
    Anticancer Res. 2023;43:305-309.
    PubMed     Abstract available


  60. FIALA O, Hosek P, Korunkova H, Hora M, et al
    Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience.
    Anticancer Res. 2023;43:463-471.
    PubMed     Abstract available


  61. FAUSTINO-ROCHA AI, Jota-Baptista C, Nascimento-Goncalves E, Oliveira PA, et al
    Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies.
    Anticancer Res. 2023;43:323-333.
    PubMed     Abstract available


  62. COLBOURNE JRM, Toniolo JT, Diacon A, Lawrentschuk N, et al
    Following the Trend: A Comparative Analysis of Public Engagement and Funding for Annual Prostate and Breast Cancer Campaigns Using Google Trends.
    Anticancer Res. 2023;43:409-415.
    PubMed     Abstract available


  63. MARTINO T, DE Bem GF, Santos SVM, Coelho MGP, et al
    LQB-118 Suppresses Migration and Invasion of Prostate Cancer Cells by Modulating the Akt/GSK3beta Pathway and MMP-9/Reck Gene Expression.
    Anticancer Res. 2023;43:359-367.
    PubMed     Abstract available


  64. LEHRER S, Rheinstein PH
    Androgen Deprivation Therapy Unrelated to Alzheimer's Disease in the UK Biobank Cohort.
    Anticancer Res. 2023;43:437-440.
    PubMed     Abstract available


  65. SCIALPI M, Martorana E, Scialpi P, Scalera GB, et al
    S-PI-RADS and PI-RRADS for Biparametric MRI in the Detection of Prostate Cancer and Post-treatment Local Recurrence.
    Anticancer Res. 2023;43:297-303.
    PubMed     Abstract available


    November 2022
  66. TAMURA M, Ueda Y, Fukunaga JI, Kamima T, et al
    Impact of Knowledge-based Plan Model Improvement on Plan Complexity and Deliverability in VMAT For Prostate Cancer: A Multi-institutional Study.
    Anticancer Res. 2022;42:5305-5314.
    PubMed     Abstract available


    October 2022
  67. LI JR, Wang SS, Chen CS, Yang CK, et al
    Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
    Anticancer Res. 2022;42:4857-4866.
    PubMed     Abstract available


  68. OKABE KO, Terada N, Shirakawa T, Onizuka C, et al
    Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel.
    Anticancer Res. 2022;42:4981-4987.
    PubMed     Abstract available


    July 2022
  69. NAKANISHI E, Hirata T, Tamari K, Isohashi F, et al
    Long-term Outcomes of Radiation Therapy for Prostate Cancer in Elderly Patients Aged >/=75 Years.
    Anticancer Res. 2022;42:3529-3536.
    PubMed     Abstract available


  70. SHEN YC, Shih HJ, Lin CC, Huang SH, et al
    Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells.
    Anticancer Res. 2022;42:3427-3434.
    PubMed     Abstract available


  71. DENG F, Kong MX, Lai J
    Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
    Anticancer Res. 2022;42:3601-3605.
    PubMed     Abstract available


  72. NIEDER C, Stanisavljevic L
    Independent Validation of a Risk Stratification Model Predicting Survival in Patients With Metastatic Hormone-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:3675-3679.
    PubMed     Abstract available


    June 2022
  73. KAMIJIMA T, Yaegashi H, Mizokami A, Nakajima K, et al
    Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
    Anticancer Res. 2022;42:3099-3108.
    PubMed     Abstract available


  74. PEPE P, Pepe L, Cosentino S, Ippolito M, et al
    Detection Rate of (68)Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer.
    Anticancer Res. 2022;42:3011-3015.
    PubMed     Abstract available


  75. FUJIMOTO N, Minato A, Igawa T, Hiroshige T, et al
    Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
    Anticancer Res. 2022;42:3041-3047.
    PubMed     Abstract available


  76. PASQUALETTI F, Calistri E, Fuentes T, Sainato A, et al
    Early Versus Late Postoperative Radiotherapy in Patients With Prostate Cancer: Results of a Single-centre Retrospective Study.
    Anticancer Res. 2022;42:2997-3001.
    PubMed     Abstract available


    May 2022
  77. REINIKAINEN P, Kapanen M, Luukkaala T, Kellokumpu-Lehtinen PL, et al
    Acute Side-effects of Different Radiotherapy Treatment Schedules in Early Prostate Cancer.
    Anticancer Res. 2022;42:2553-2565.
    PubMed     Abstract available


    April 2022
  78. IWAMOTO H, Nakagawa R, Makino T, Kadomoto S, et al
    Treatment Outcomes in Neuroendocrine Prostate Cancer.
    Anticancer Res. 2022;42:2167-2176.
    PubMed     Abstract available


  79. FUJIWARA M, Fujiwara R, Oguchi T, Komai Y, et al
    Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy.
    Anticancer Res. 2022;42:2123-2130.
    PubMed     Abstract available


  80. NEUBERGER M, Skladny J, Goly N, Wessels F, et al
    Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy.
    Anticancer Res. 2022;42:1911-1918.
    PubMed     Abstract available


  81. KATSUTA M, Kimura T, Tashiro K, Murakami M, et al
    Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.
    Anticancer Res. 2022;42:2023-2028.
    PubMed     Abstract available


    March 2022
  82. PEPE P, Pennisi M
    Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer?
    Anticancer Res. 2022;42:1495-1498.
    PubMed     Abstract available


  83. MIZOKAMI A, Nishimoto K, Matsuyama H, Ichikawa T, et al
    Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice.
    Anticancer Res. 2022;42:1465-1475.
    PubMed     Abstract available


  84. LIU C, Zhou Y, Zhou YU, Xu Z, et al
    Kindlin-3 in Immune Cells Is Required to Suppress Prostate Cancer Tumor Growth in Mice.
    Anticancer Res. 2022;42:1217-1220.
    PubMed     Abstract available


    February 2022
  85. NAGATA Y, Matsukawa T, Tomisaki I, Fujimoto N, et al
    Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:1107-1114.
    PubMed     Abstract available


  86. SHIMADA T, Izumi K, Kano H, Kadomoto S, et al
    Ra-223 and Ethinylestradiol Combination Therapy in Castration-resistant Prostate Cancer.
    Anticancer Res. 2022;42:1065-1071.
    PubMed     Abstract available


    January 2022
  87. IACOVELLI R, Ciccarese C, Caffo O, De Giorgi U, et al
    The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:165-172.
    PubMed     Abstract available


  88. LEHTONEN M, Sormunen J, Hjalm-Eriksson M, Thellenberg-Karlsson C, et al
    Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
    Anticancer Res. 2022;42:87-92.
    PubMed     Abstract available


    December 2021
  89. XIE F, Peng F
    Reduction in Copper Uptake and Inhibition of Prostate Cancer Cell Proliferation by Novel Steroid-based Compounds.
    Anticancer Res. 2021;41:5953-5958.
    PubMed     Abstract available


    November 2021
  90. BLAS L, Ieiri K, Shiota M, Nagakawa S, et al
    Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer.
    Anticancer Res. 2021;41:5593-5598.
    PubMed     Abstract available


    October 2021
  91. KOPELKE S, Bartscht T, Schild SE, Tvilsted S, et al
    Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy.
    Anticancer Res. 2021;41:5165-5169.
    PubMed     Abstract available


  92. TAKAI M, Kawakami K, Fujita Y, Kato T, et al
    Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear Localization.
    Anticancer Res. 2021;41:4753-4759.
    PubMed     Abstract available


  93. FUJIMOTO N, Harada K, Shiota M, Tomisaki I, et al
    Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Anticancer Res. 2021;41:4687-4695.
    PubMed     Abstract available


  94. KARLSSON S, Diaz Cruz MA, Faresjo M, Khamou AP, et al
    Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D3 in LNCaP Cells.
    Anticancer Res. 2021;41:4733-4740.
    PubMed     Abstract available


    September 2021
  95. MASUDA H, Fujimoto A, Kanesaka M, Hou K, et al
    Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer.
    Anticancer Res. 2021;41:4443-4446.
    PubMed     Abstract available


  96. MIYATA Y, Masato M, Mukae Y, Nakamura Y, et al
    Pathological Roles of Prostaglandin E2-specific E-type Prostanoid Receptors in Hormone-sensitive and Castration-resistant Prostate Cancer.
    Anticancer Res. 2021;41:4333-4341.
    PubMed     Abstract available


  97. JACEWICZ M, Rud E, Galtung KF, Noor D, et al
    Cancer Detection Rates in Targeted Transperineal MRI-TRUS Elastic Fusion-guided Prostate Biopsies Performed Under Local Anesthesia.
    Anticancer Res. 2021;41:4395-4400.
    PubMed     Abstract available


    August 2021
  98. JIMENEZ ROMERO ME, Gallego MC, Navarro Serrato JC, Sanchez Hurtado MA, et al
    Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors.
    Anticancer Res. 2021;41:3955-3968.
    PubMed     Abstract available


  99. BLAS L, Shiota M, Yamada S, Ieiri K, et al
    Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.
    Anticancer Res. 2021;41:3885-3889.
    PubMed     Abstract available


  100. WATANABE H, Kawakami A, Sato R, Watanabe K, et al
    Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
    Anticancer Res. 2021;41:3753-3758.
    PubMed     Abstract available


  101. OELRICH F, Junker H, Stope MB, Erb HHH, et al
    Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery.
    Anticancer Res. 2021;41:3717-3729.
    PubMed     Abstract available


  102. STELLER D, Simon R, VON Bialy R, Hakim SG, et al
    Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
    Anticancer Res. 2021;41:3917-3923.
    PubMed     Abstract available


    July 2021
  103. HARADA J, Miyata Y, Taima T, Matsuda T, et al
    Stage-specific Embryogenic Antigen-4 Expression in Castration-resistant Prostate Cancer and its Correlation With the Androgen Receptor.
    Anticancer Res. 2021;41:3327-3335.
    PubMed     Abstract available


  104. ERB HHH, Oster MA, Gelbrich N, Cammann C, et al
    Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System.
    Anticancer Res. 2021;41:3271-3279.
    PubMed     Abstract available


    June 2021
  105. PEPE P, Pepe L, Pennisi M, Fraggetta F, et al
    Prostate Cancer Diagnosis and Management During One Year of the COVID-19 Pandemic.
    Anticancer Res. 2021;41:3127-3130.
    PubMed     Abstract available


  106. GARRIDO MM, Ribeiro RM, Kruger K, Pinheiro LC, et al
    Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?
    Anticancer Res. 2021;41:3067-3073.
    PubMed     Abstract available


    May 2021
  107. ITO M, Sasamura K, Takase Y, Kotsuma T, et al
    Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer.
    Anticancer Res. 2021;41:2523-2531.
    PubMed     Abstract available


  108. IINUMA K, Kawakami K, Mizutani K, Fujita Y, et al
    miRNA-93 in Serum Extracellular Vesicles Before and After Low Dose Rate Prostate Brachytherapy.
    Anticancer Res. 2021;41:2411-2418.
    PubMed     Abstract available


    April 2021
  109. SEKITO S, Terabe T, Shibahara T, Onishi T, et al
    Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer.
    Anticancer Res. 2021;41:2183-2186.
    PubMed     Abstract available


  110. FERINI G, Tripoli A, Molino L, Cacciola A, et al
    How Much Daily Image-guided Volumetric Modulated Arc Therapy Is Useful for Proctitis Prevention With Respect to Static Intensity Modulated Radiotherapy Supported by Topical Medications Among Localized Prostate Cancer Patients?
    Anticancer Res. 2021;41:2101-2110.
    PubMed     Abstract available


  111. HAN Q, Hoffman RM
    Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
    Anticancer Res. 2021;41:1921-1926.
    PubMed     Abstract available


    March 2021
  112. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.